Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jazz' $700 million EUSA buy diversifies portfolio and broadens reach

This article was originally published in Scrip

Executive Summary

Jazz Pharmaceuticals PLC will increase its international presence and diversify its specialty pharma portfolio with the $700 million purchase of EUSA Pharma.

You may also be interested in...

Stockwatch: Is Biotech Investing A State Of Mind?

The American Society for Clinical Oncology (ASCO) conference that has just opened in Chicago is traditionally thought of as one of the key catalysts of the year for biotechnology and pharmaceutical companies. The stock prices of companies presenting their latest data usually run up in anticipation of ASCO and subsequently sell off after the conference. While this is now expected by investors, this year may be different.

Ionis Invests For The Future In New Technologies, Manufacturing Innovation

Through partnerships with Bicycle and Metagenomi, Ionis is working on new chemistries and novel medicines. It is also expanding manufacturing capacity to enable its scientific growth.

Ionis Finds Its Footing Ahead Of Its First Big Commercial Step

Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts